Release

<< Back
Sep 24, 2018

Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals A/S

Company Announcement no. 17/2018

To: NASDAQ Copenhagen A/S                                            

Copenhagen, Denmark, 24 September 2018

Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Morten Marott has chosen to step down as Chief Financial Officer effective immediately.  Ira Duarte, vice-president of finance for Veloxis Pharmaceuticals Inc., will assume the role of interim Chief Financial Officer. 

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said “We greatly appreciate Morten’s contributions to the company and wish him all the best in his future endeavors.”

For more information, please contact:

Craig A. Collard                                         
President & CEO                                       
Phone: +1 919 591 3090                         
Email: cac@veloxis.com                           

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

 

Attachment